Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMM 101

Next Previous
Drug Profile

IMM 101

Alternative Names: Heat-killed whole cell Mycobacterium obuense; IMM-101; NCTC 13365

Latest Information Update: 19 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immodulon Therapeutics
  • Developer Canadian Cancer Trials Group; Erasmus MC; Immodulon Therapeutics; Ontario Institute for Cancer Research; Roche
  • Class Antineoplastics; Antivirals; Bacteria; Immunotherapies
  • Mechanism of Action Dendritic cell stimulants; Toll-like receptor 1 agonists; Toll-like receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections
  • Phase II Colorectal cancer; Malignant melanoma; Pancreatic cancer
  • Phase I/II Cancer

Most Recent Events

  • 19 Dec 2024 Phase-III clinical trials in COVID-2019 infections (Prevention) is ongoing in Canada (Intradermal)(NCT04442048)
  • 13 Sep 2024 Efficacy and adverse events data from phase-I/II clinical trials in Pancreatic cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 11 Dec 2023 Immodulon plans a late-stage pivotal clinical trial for Pancreatic cancer (Intradermal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top